Peer-Reviewed Journal Details
Mandatory Fields
Grossjohann, C,Eccles, KS,Maguire, AR,Lawrence, SE,Tajber, L,Corrigan, OI,Healy, AM
2012
January
International Journal of Pharmaceutics
Characterisation, solubility and intrinsic dissolution behaviour of benzamide: dibenzyl sulfoxide cocrystal
Published
()
Optional Fields
Intrinsic dissolution Cocrystals Solubility Complexation HPLC INDOMETHACIN-SACCHARIN COCRYSTALS PHARMACEUTICAL COCRYSTALS PHASE-DIAGRAMS ROTATING-DISK CO-CRYSTAL ACID BIOAVAILABILITY COMPOSITES GABAPENTIN APPARATUS
422
24
32
This study examined the 1:1 cocrystal benzamide: dibenzyl sulfoxide, comprising the poorly water soluble dibenzyl sulfoxide (DBSO) and the more soluble benzamide (BA), to establish if this cocrystal shows advantages in terms of solubility and dissolution in comparison to its pure components and to a physical mixture. Solubility studies were performed by measuring DBSO solubility as a function of BA concentration, and a ternary phase diagram was constructed. Dissolution was examined through intrinsic dissolution studies. Solid-state characterisation was carried out by powder X-ray diffraction (PXRD), energy-dispersive X-ray diffraction (EDX), infra-red spectroscopy (ATR-FTIR) and thermal analysis. DBSO solubility was increased by means of complexation with BA. For the cocrystal, the solubility of both components was decreased in comparison to pure components. The cocrystal was identified as metastable and incongruently saturating. Dissolution studies revealed that dissolution of DBSO from the cocrystal was not enhanced in comparison to the pure compound or a physical mix, while BA release was retarded and followed square root of time kinetics. At the disk surface a layer of DBSO was found. The extent of complexation in solution can change the stability of the complex substantially. Incongruent solubility and dissolution behaviour of a cocrystal can result in no enhancement in the dissolution of the less soluble component and retardation of release of the more soluble component. (C) 2011 Elsevier B. V. All rights reserved.
DOI 10.1016/j.ijpharm.2011.10.016
Grant Details